ArticleClinical drug investigation2026

Cost-Effectiveness Analysis of Anlotinib Plus Penpulimab Versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma in China.

JinDi Liu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.